美国华人生物医药科技协会第25届年会

Rockville, Maryland, USA

# The 25th Annual Conference (Virtual)

# Chinese Biopharmaceutical Association



## Innovations Amid Crisis:

### A Productive Year of Biopharma Industry

### August 29-30, 2020

In Collaboration with CBA-Canada

"The Bridge of US-China Biopharmaceuticals"

# WELCOME LETTER FROM CBA PRESIDENT

Dear CBA-USA Members and Friends,

It is my great pleasure to welcome you to the 25th Annual Conference of Chinese Biopharmaceutical Association-USA (CBA). CBA was established in 1995 to provide a platform for, but not limited to, Chinese American biopharmaceutical professionals to network and exchange ideas. Over the past quarter century, CBA has witnessed the early days of biopharma industry and its booming growth, which tremendously expanded the arsenal to treat human diseases and thus greatly contributed to overall well-being of humankind. However, we are also witnessing one of the biggest social-economic crises in the past 25 years, caused by the ongoing pandemic of a novel coronavirus disease named COVID-19. Schools are closed, businesses are shut down, most of human activities are limited to home, the whole society has come to a stop, with people anxiously waiting for a solution. This is the time when we as biopharma professionals never feel so proud to be part of history. CBA members and friends, along with other bio-scientists all over the world, are working extremely hard on the first line to combat this havoc-wreathing disease. As of now, we already accumulated plenty of information about the virus's nature and how to deal with it. Vaccines and therapeutic drugs are on the verge of being brought to the public. At this exciting moment when dawn is about to break, CBA has invited some of the world's most prominent COVID-19 experts to share their findings and thoughts at CBA's Annual Conference. Latest developments in COVID-19 strategic management, epidemiology, vaccine and drug development, virology as well as FDA regulations will be extensively discussed. Although COVID-19 posed great obstacles, biopharma industry still advances rapidly amid the crisis. The exciting new developments in the fields of cell and gene therapy, human longevity and cancer drug development will also be discussed in the conference.

This event is co-sponsored by Maryland Department of Commerce, with supports from CBA-Canada and Society of Chinese Bioscientists in America (SCBA) Washington-Baltimore Chapter. CBA has received very generous support this year from our sponsors including biopharmaceutical companies, contract research organizations (CROs), biotech service providers, and medical device companies operating in China, the USA, and Canada. On behalf of CBA, I would like to sincerely thank all of our sponsors for their strong commitments and contributions to this conference.

As Chair of this year's Conference Organizing Committee, I would like to express my sincere gratitude to all committee members and the many CBA members who have worked so diligently to ensure success of this year's event. I am very grateful to your commitments and dedications to this conference.

Sincerely,

Dazhi (Alex) Lai, Ph.D.
President, Chinese Biopharmaceutical Association-USA
Chair, the 25th CBA Annual Conference Organizing Committee

## CBA History and Accomplishments (1995-2020)

The Chinese Biopharmaceutical Association-USA (CBA-USA) (www.cba-usa.org) is one of the largest Chinese American professional associations in the US. CBA was founded in 1995 by a group of Chinese American biopharmaceutical professionals as a non-political and non-profit organization headquartered in the Washington DC area.

The mission of CBA is to promote communication and collaboration among biopharmaceutical professionals and to foster business collaborations among different countries and regions, especially between the US and China.

CBA has an excellent reputation both in China and the US for developing and enhancing friendship and cooperation in the biopharmaceutical and life sciences industries. Our efforts have been applauded by industry executives and prominent leaders from both the US and China. The former China Minister of Health, Dr. Zhu Chen, former US Deputy Secretary of Labor, Samuel Tingsing Mok, former Chinese Ambassadors to the US, Wenzhong Zhou and Daoyu Li, and dozens of prominent leaders from academia, industry and government have attended and addressed at CBA's events. A number of prestigious scientific journals, including Nature, Science, and Bioprocess International, have reported on the CBA, its event, as well as its members.

Since its establishment, CBA has stayed true to its mission in bridging the biopharmaceutical industry between the US and China. Its signature event, the CBA Annual Conference, which has been successfully held in the US or in China for 23 years, has served as an effective platform that brought together the elite scientific minds, successful entrepreneurs, and government agencies in the pharmaceutical and biotechnology areas. Some of the key topics at the past CBA annual conferences included:

- Cutting edge sciences and technologies in the development of medicines
- Commercialization and globalization of biopharmaceutical development through partnerships
- Regulatory perspectives of pharmaceutical development

In addition to the Annual Conferences, CBA has hosted and co-hosted (with American and Chinese professionals and industrial organizations in biopharmaceutical areas) a large number of workshops and seminars focusing on local and international hot topics, and cutting-edge research and technology discoveries. The most recent events include:

- The 9th Human Vaccine Industry Summit 2017, Qingdao, China
- Shanghai BioPharm Forum 2017, Shanghai, China
- Precision Medicine and Immuno-Oncology China 2017, Shanghai, China
- Asia Pharma R&D Summit 2017, Shanghai, China

## CBA - INTRODUCTION

In the past 25 years, CBA has also served as an incubator for talents and entrepreneurs, and a place for professional networking and development. Many former CBA presidents and board members are now established industry leaders in the US and China, such as Dr. Guoliang Yu, Chairman of CrownBio, Dr. Dajun Yang, Chairman and CEO of Acentage, Dr. Dan Zhang, Chairman of Fountain Medical Development, Dr. Patrick Lu, Chairman and CEO of Sirnaomics, Dr. Dong Xie, Chairman and COO of Frontier Biotechnologies, Dr. Yingxian Xiao, CEO of Shanghai Furen Medicine, Dr. Sujuan Ba, President and COO of National Foundation for Cancer Research, and biotech entrepreneur stars such as Dr. Ping Chen and Dr. Ziping Wei.

Since 2016, CBA has started to organize bimonthly workshops to provide opportunities for sharing expertise and discussing latest topics by experts. CBA also helps members with their career development in the biopharmaceutical industry. Each of these events attracted hundreds of medical, clinical and pharmaceutical students and professionals who were seeking new or advanced career opportunities.

In 2018, CBA launched new initiatives to form multiple small study groups to discuss innovative trends in the biopharmaceutical industry. These are venues for members to share expertise and deepen their knowledge. The Biomarker and Diagnostics Study Group, composed of 19 CBA active members, kicked off the series of activities on May 06, 2018. Other study groups covering other latest trends in drug development are in progress.

CBA is also a place where Chinese American pharmaceutical professionals meet and network. Over the years, the annual CBA Chinese New Year Galas and annual Fall Picnics provide relaxing and fun opportunities for CBA members to connect and celebrate.

The success of the organization is attributed to the active involvement of members around the US who strongly believe in its mission. Today, the global biopharmaceutical and healthcare industry continues to evolve and grow, particularly in China and the Asia Pacific area. The CBA members are ready to rise to the challenges ahead.

Through the persistent efforts of the CBA's strong leadership, its devoted members and volunteers, its sponsors and supporters in the past 25 years, CBA has become a well-recognized Chinese American professional organization with more than 8000 members in the US, China, and the rest of the world.

CBA Sponsors & Donations, please mail to:
P. O. Box 61362
Potomac, MD 20859-1362

CBA Membership Registration: please extract QR code form below:

# TABLE OF CONTENTS

WELCOME LETTER FROM CBA PRESIDENT . . . . . 2

CBA HISTORY AND ACCOMPLISHMENTS (1995-2020). . . . . 3

CBA EXECUTIVE PRESIDENTS . . . . . 6

CONFERENCE AGENDA. . . . . 7

SPEAKERS BIOGRAPHY IN ALPHABETICAL ORDER . . . . . 9

CBA BRILLIANT ACHIEVEMENT AWARD RECIPIENTS. . . . . 16

CBA OUTSTANDING SERVICE AWARD RECIPIENTS. . . . . 16

CBA PAST PRESIDENTS AND CONFERENCES. . . . . 17

ANNUAL CONFERENCE ORGANIZING COMMITTEE . . . . . 18

# CBA EXECUTIVE PRESIDENTS

**DAZHI (ALEX) LAI, PH.D.**
Incumbent President of CBA
(2020-2021)

Dr. Lai graduated from Nankai University and obtained his Ph.D. from Beijing Institute of Microbiology and Epidemiology. After postdoctoral training at Yale University and NIH, Dr. Lai founded SPEED Biosystems, a global biomedical research solution provider to academia, industry and government agencies, and serves as the company's CEO until now. Dr. Lai has been a member of Board of Directors of CBA since 2012.

---

**CHUANHUA JULIA XING, PH.D.**
Immediate Past President of
CBA (2019-2020)

Dr. Xing is the founder of ShiHua Health Company for AI products in biomarker diagnosis, clinical solutions and drug development. She gained Ph.D. from NC State University and postdoc training from Duke University. She worked as an Assistant Professor at Boston University, a visiting professor at Sun Yat-sen University, a Principal Statistician at AstraZeneca-MedImmune and a Sr. Advisor Statistician for the development of three new drugs for DoD at GDIT-Dynport Vaccine Company. She participated in the nationwide representative studies such as the Framingham Heart Study and the CHARGE Sequencing. She led the second stage drug improvement of non-small cell lung cancer drug Imfinzi at Astrazeneca-MedImmune, and the development and management of four vaccines including rF1V, rBV A/B, huBChE and FluMist. She published nearly 30 papers, with most as the major author at the top tier journals in the field of statistics, AI and medicine. She also won multiple research and leadership awards, and presented more than 60 times in national/international meetings, universities, and pharmaceutical companies.

Dr. Xing also served for other meetings and organizations such as the Joint Statistical Meeting (the organizer/chair) and the Committee on Nominations for Caucus for Women in Statistics, American Association of Statistics.

---

**FRANK LI LI, M.D., PH.D.**
Former President of CBA
(2018-2019)

Dr. Li obtained his PhD degree in Molecular Medicine from Kyoto University, School of Medicine, Japan. He did medical residency in surgical departments in Beijing followed by clinical research training for his master's degree in China-Japan Friendship Hospital and Peking Union Medical College in Beijing, China. Dr. Li has been working in the Biopharmaceutical industry for more than 15 years including experiences in CROs and drug developers such as AstraZeneca and MedImmune. Dr. Li contributed to the development of FASENRA (an anti-IL5R antibody for Asthma) from Ph-2 to BLA regulatory defense leading to Regulatory approvals in world major markets. Dr. Li has been a volunteer to communities including CBA for many years. Dr. Li was the head of US operations for Ascentage Pharma Group Inc. and also continues to Regulatory Affairs Projects management.

As the Chairman of CBA organizing committee, Dr. Li has successfully organized the 23rd Annual Conference in June 2018 with more than 800 attendees and famous Keynote Speakers from academia, regulatory authority, and industry including Drs. Lieping Chen (Yale University, Professor), Richard Pazdur (FDA, Center Director), Yongjun Liu (Sanofi, Global R&D Head), and Laurence Cooper (ZioPharm CEO).

Now Dr. Li is the founder of his own company, BLA Regulatory, which provides consulting services in Regulatory Affairs.

# CONFERENCE AGENDA DAY ONE: AUGUST 29, 2020 SATURDAY

## Welcome to CBA 25th Annual Conference

**7:30-7:40**

**Dr. Dazhi (Alex) Lai** CBA President

## Opening Remarks

**7:40-7:45**

**Hon. John C. Wobensmith** Maryland Secretary of State

## Opening Remarks

**7:45-8:00**

**Dr. Ernesto Chanona** Senior Manager, Office of BioHealth and Life Sciences, Maryland Department of Commerce

**Felicia M. Pullam** Regional Manager, East Asia, Maryland Department of Commerce

## Session I: Covid-19 Pandemic Impact and Management

**Chairs:**

**Dr. Richard Zhao**
Professor, University of Maryland

**Dr. Yuling Wu**
Head of Discovery Bioanalysis US, AstraZeneca

**8:00-8:35**

**Dr. George F. Gao** Professor, Chinese Academy of Sciences; Director of Center of Disease Control, China
***Keynote Speech:* COVID-19: Challenge and Opportunity.**

**8:35-9:10**

**Dr. Peter Stein** Director, Office of New Drugs, FDA
***Keynote Speech:* Drug Regulations in the Time of COVID-19: Trials (and Tribulations)**

**9:10-9:35**

**Dr. Mark Esser** VP and Head of Microbial Sciences, AstraZeneca
**The Great Race of Mercy 2020**

**9:35-10:00**

**Dr. Wen-Hong Zhang** Professor, Fudan University Huashan Hospital
**High Effective Preparedness and Response Strategies to Public Health Emergencies**

**10:00-10:25**

**Dr. Anant Jani** Research Fellow, Oxford University
**"COVID-19's Aftermath: Lessons from the 2008 Global Financial Crisis"**

## Session II: COVID-19 Prevention, Treatment and Epidemiology

**Chairs:**

**Dr. Mitchell Ho**
Senior Investigator, NIH

**Dr. Julia Xing**
CEO, XPrecision

**10:25-11:00**

**Dr. Nilanjan Chatterjee** Professor, Johns Hopkins University
***Keynote Speech:* Individual and Population-Level Risk Assessment for COVID-19 Mortality in US**

**11:00-11:25**

**Dr. Jinghua Yan** Professor, Chinese Academy of Sciences
**Neutralizing mAbs for SARS-CoV-2**

**11:25-11:50**

**Dr. Shou-Bai Chao** COO, CanSino Biologics
**Development of an Effective Vaccine Against COVID-19**

**11:50-12:15**

**Dr. Joan Shen** CEO, I-Mab Biopharma
**GM-CSF as a Potential Treatment Option for Cytokine Release Syndrome Associated with Severe COVID-19**

**12:15-12:40**

**Dr. Dong Shen** CEO, RNAimmune
**Frontiers of COVID-19 Vaccine Development**

# CONFERENCE AGENDA DAY TWO: AUGUST 30, 2020 SUNDAY

## Session III: COVID-19 Virology

**Chairs:**
**Dr. Xuefeng Liu**
Professor, Georgetown University

**Dr. Zhi-Ming Zheng**
Senior Investigator, NIH

**8:00-8:30**
**Dr. Tongqing Zhou** Chief, Structural Bioinformatics Core Section, VRC, NIH
**Structural Biology of SARS-CoV-2 and Structure-Based Vaccine Design**

**8:30-9:00**
**Dr. Yang Liu** Professor, University of Maryland
**Pattern Recognition of Danger-Associated Molecular Patterns and Immunotherapy of COVID-19**

## Session IV: Vaccine Development

**Chair:**
**Dr. Helen Mao**
SVP of CanSino Biologics

**9:00-9:35**
**Dr. George Siber** Director and Co-Founder, Affinivax; Adjunct Professor, Johns Hopkins University
***Keynote Speech:* Bacterial Conjugate Vaccines – Status in 2020**

## Session V: Cell and Gene Therapy

**Chairs:**
**Dr. Xiaobin Victor Lu**
SVP, Innovative Cellular Therapeutics

**Dr. Xu-Rong Jiang**
Senior Director of Quality and Technical, AstraZeneca

**9:35-10:10**
**Dr. Frank Fan** Co-Founder and CSO, Legend Biotech
***Keynote Speech:* Clinical Progress & Global Competition in BCMA-targeted Immunotherapy**

**10:10-10:35**
**Dr. Yihong Yao** CSO, Cellular Biomedicine Group (CBMG)
**Building a Competitive Cell Therapy Pipeline for Cancer Patients**

**10:35-11:00**
**Dr. Mitchell Ho** Senior Investigator, NIH
**GPC-3 as a Liver Cancer Target of CAR T Cell Therapy**

## Section VI: CBA Former Presidents Special: New Breakthroughs in Health and Disease

**Chairs:**
**Dr. Frank Li**
Founder, BLA Regulatory

**Dr. Song Wu**
Associate Director of Oncology Translational Medicine, AstraZeneca

**11:00-11:30**
**Dr. Dajun Yang** CEO, Ascentage Pharma
**Signals of Life and Death: Harnessing Apoptosis to Treat Cancers**

**11:30-12:00**
**Dr. Wei-Wu He** Executive Chairman, Human Longevity Inc.
**Scientific Solutions for Human Longevity and Performance**

## Closing Remarks

**12:00-12:20**
**Dr. Chuanhua Julia Xing** CBA Immediate Past President

## Announcement of CBA's President-Elect for 2021-2022

**12:20-12:30**
**Dr. Dazhi (Alex) Lai** CBA President

# SPEAKERS BIOGRAPHY IN ALPHABETICAL ORDER

## DR. ERNESTO CHANONA, PH.D.

Ernesto is currently Senior Manager, Office of BioHealth and Life Sciences, Maryland Department of Commerce.

Ernesto focuses on the economic development of the biotechnology and medtech sectors for the State of Maryland. He is also an Adjunct Professor at the Johns Hopkins University, Center for Biotechnology Education. He trained as a cancer immunologist and worked in the pre-clinical development of immunotherapies at the National Cancer Institute.

As a business and innovation development expert, Ernesto helps local companies overcome challenges in commercialization. These include obtaining funding, real estate, academic research partners, federal lab innovations and connections to local CXOs. He has developed a program called the Maryland Innovation and Technology Series that fosters the transfer of technology and talent from the National Institutes of Health to Maryland's biotechnology companies.

Internally, Ernesto serves as a market analyst. His primary research interests include the growth, structure and dynamics of biotechnology hubs. By analyzing the relationships between the stakeholders in industry, the output of biotechnology talent pipelines, the priorities of government agencies, and the appetite of investment community, he develops local and international strategies that best foster the growth of industry.

## DR. SHOU-BAI CHAO, PH.D.

Dr. Shou-Bai Chao is currently Chief Operations Officer of CanSinoBIO (6185.HK). He is a senior executive and well-sought industry leader who brings comprehensive perspective with more than 25 years' experience from AstraZeneca, Wyeth, Sanofi-Pasteur and Genentech in global vaccine and biopharmaceutical process and product development, manufacturing operations, quality assurance and business management.

Dr. Chao is the former Senior Vice President at AstraZeneca (MedImmune). Prior to joining CanSinoBIO in 2018, Dr. Chao was leading AstraZeneca's Bioventure business unit to develop Biosimilars and BioBetters for global markets with leading biotech companies in US, Europe, China and other Asian countries.

Dr. Chao joined MedImmune, a Biopharmaceutical Division of AstraZeneca in 2008 as Vice President of Vaccines Manufacturing, responsible for global operations of its vaccine business. During 2009 H1N1 Pandemic, Dr. Chao led the team and developed and licensed the first H1N1 Pandemic FluMist vaccine in US which was ahead of all other companies and was well recognized by the HHS and the industry. Dr. Chao was promoted to Senior Vice President of Technical Operations and Manufacturing in 2010 at AstraZeneca, responsible for global operations of commercial and later stage clinical products (vaccines and antibodies) manufacturing and technical operations.

Prior to joining MedImmune, Dr. Chao served as Assistant Vice President, Technical Operations and Product Supply at Wyeth Biotech (Pfizer). He was responsible for global technical operations for flagship vaccines and other biopharmaceutical products.
Dr. Chao earned his doctorate degree and completed his postdoctoral fellowship in biochemical engineering from University of Waterloo, Canada.

## DR. NILANJAN CHATTERJEE, PH.D.

Dr. Nilanjan Chatterjee is a Bloomberg Distinguished Professor of Biostatistics and Genetic Epidemiology at Johns Hopkins University, with appointments in the Department of Biostatistics in the Bloomberg School of Public Health and in the Department of Oncology in the Sidney Kimmel Comprehensive Cancer Center in the Johns Hopkins School of Medicine. He was formerly the chief of the Biostatistics Branch of the National Cancer Institute's Division of Cancer Epidemiology and Genetics.

Dr. Chatterjee leads a broad research program in quantitative research that cuts across multiple areas of modern population-based biomedical science including statistical genetics/genomics, precision medicine and big data. The scientific goals of his studies include discovery of new biomarkers, understanding disease mechanisms, characterizing disease risk and developing risk-stratified approaches to disease prevention. He has extensively collaborated in recent genome-wide association studies that have led to identification new cancer susceptibility SNPs, provided characterization of heritability, genetic architecture and gene-environment interaction, and led to better understanding of potential for genetic risk stratification for cancer prevention.

Dr. Chatterjee is a recipient of numerous awards, including Fellow of the American Statistical Association (2008), Mortimer Spiegelman Award (2010), George W. Snedecor Award (2011), COPSS Presidents' Award (2011), Gertrude Cox Award (2011) and Elected Member of the American Epidemiologic Society (2012).

# SPEAKERS BIOGRAPHY IN ALPHABETICAL ORDER

## DR. MARK ESSER, PH.D.

Dr. Esser is Vice President of Microbial Sciences at AstraZeneca. In this role he is accountable for AstraZeneca's overall drug discovery, translational research and clinical development of innovative medicines targeting for the microbiome, infectious disease and in vivo expressed biologics. He is experienced in drug discovery through registrational and post-marketing studies and has contributed to 4 different biologics licensing agreements. He has several patents and is widely recognized for his contributions to infectious disease research and global health with over 75 peer-reviewed publications. Dr. Esser received his B.S. in biochemistry from Case Western Reserve University, his doctorate in microbiology and immunology from University of Virginia and did his postdoctoral fellowship at the AIDS vaccine program at the NIH.

## DR. FRANK FAN, M.D., PH.D.

Dr. Fan is the co-founder of Legend Biotech and currently serves the company as the Chief Scientific Officer. Dr. Fan received his medical degree at Xi'an Jiaotong University in 1993 and worked as a surgical resident in the kidney Transplantation Centre of the university before he pursued his Ph.D. in applied immunology at Hiroshima University, Japan. He completed his postdoctoral training at the Hospital for Sick Children, University of Toronto, Canada where he became recognized as an expert in the field of the mechanism of human B cell tolerance.

Dr. Fan has been published in numerous peer-reviewed academic journals, including an original article published in Nature Medicine which lead to a major revision in the clinical guidelines of pediatric organ transplantation. Dr. Fan's scientific achievement paved the way by showing that small children can be safely transplanted with ABO blood group mismatched organs, and saved many lives of infant patients. Dr. Fan was awarded the"New Key Opinion Leader"award by The Transplantation Society in 2006.

Dr. Fan founded Legend Biotech in 2015 and the company grew into a global leader in cancer immunotherapy in just 5 years. A bispecific BCMA-targeting CAR-T product Dr. Fan invented entered a global partnership with Janssen to co-develop the global markets. The product received breakthrough designation from the FDA and PRIME scheme from the EMA. Dr. Fan is now leading the world's largest cell therapy R&D team and is devoted to inventing more innovative technologies for treating solid tumors and other diseases.

## DR. GEORGE F. GAO, DPHIL (OXON), MSC

Dr. Gao currently holds several positions:

1) Director-General, Chinese Center for Disease Control and Prevention (China CDC)
2) Vice President, National Natural Science Foundation of China
3) Director and Professor, CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences
4) Visiting professor, Oxford University

His Society services Include:

1) President of Chinese Society of Biotechnology
2) Vice president of Chinese Medical Association
3) Vice Chair of Division of Virology, International Union of Microbiological Societies (IUMS)

Dr. Gao obtained his PhD (DPhil) degree from Oxford University, UK and did his postdoc work in both Oxford University and Harvard University (with a brief stay in Calgary University). His research interests include enveloped viruses and molecular immunology. His group research is mainly focusing on the enveloped virus entry and release, esp. influenza virus interspecies transmission (host jump), structure-based drug-design and structural immunology. He is also interested in virus ecology, esp. the relationship between influenza virus and migratory birds or live poultry markets and the bat-derived virus ecology and molecular biology. He has published more than 600 refereed papers (Including papers in Cell, Nature, Science, The Lancet, New England Journal of Medicine, Proceedings of the National Academy of Sciences USA etc.), 17 books or book chapters and holds more than 25 UK, US and Chinese patents. His research has recently expanded on public health policy and global health strategy. He led the China CDC team in 2014 (From September to November, when the disease went to its sky-high level) to work in Sierra Leone for fighting against Ebola and his heroic role there has made a great deal for the field work. He works hard now for establishing an Africa-based center for pathogens and tropical diseases.

# SPEAKERS BIOGRAPHY IN ALPHABETICAL ORDER

Dr. Gao is a member (academician) of Chinese Academy of Sciences (elected in 2013), a fellow of The Third World Academy of Sciences (TWAS, also known as The World Academy of Sciences, elected in 2014), a fellow of American Academy of Microbiology (AAM, elected in 2015); an associate (foreign) member of European Molecular Biology Organization (EMBO, elected in 2016), a fellow of American Association for the Advancement of Science (AAAS, elected in 2016), a fellow of Royal Society of Edinburgh (RSE, elected in 2017), a fellow of African Academy of Sciences (AAS, elected in 2017), a member (academician) of International Eurasian Academy of Sciences (IEAS, elected in 2019), a foreign associate of National Academy of Sciences (NAS, elected in 2019), a member of National Academy of Medicine (NAM, elected in 2019), a member of Brazilian Academy of Sciences (BAS, elected in 2019), a member of The German National Academy of Sciences Leopoldina.

Dr. Gao is a recipient of several international and national awards, including Thompson Reuters Research Front Award (2008), TWAS Medical Prize (2012), Nikkei Asian Prize (Japan 2014), Tan Jiazhen (C. C. Tan) Grand Scientific Achievement Prize (2014) and Life Science Innovation Award (2008), HLHL S&T Advancement Award (2015), JP Wu-Paul Janssen (Medical and Pharmaceutical) Award (2015), Japanese Foreign Minister's Commencement (2015), Shulan Medical Sciences Award (2016), the Gamaleya Medal (Russia 2018) and HKU Centennial Distinguished Chinese Scholar (2019).

DR. WEI-WU HE, PH.D.

Dr. Wei-Wu He received a Bachelor's degree in Biochemistry from Nanjing University, P. R. China. Dr. He was funded by the CUSBEA (China–United States Biochemistry Examination and Application) program in 1986 and received his Ph.D. in Molecular Biology from Baylor College of Medicine. He conducted cancer research at Mayo Clinic and at Massachusetts General Hospital for many years. In 1993, Dr. He joined Human Genome Sciences, Inc., the world's first large-scale genomics company, founded by Dr. Venter. In 1996, he founded OriGene Technologies, Inc. and then established Emerging Technology Partners, LLC (ETP), which focused on early-stage venture capital in biomedical field in 2000. ETP has invested and founded more than 50 companies, including CASI pharmaceuticals, Inc, Genetron Health, Inc, Clinical Data, Inc., Dynavax Technology, Inc, MacroGenics, Inc. Dr. He is currently the chairman of CASI pharmaceuticals, Inc, OriGene Technologies, Inc, Genetron Health, Inc, Juventas and Human Longevity Inc.

DR. MITCHELL HO, PH.D.

Dr. Mitchell Ho is a Senior Investigator, the Deputy Chief of the Laboratory of Molecular Biology and the Director of the Antibody Engineering Program at the Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH). Dr. Ho is also the Chair of the Department of Biochemistry for FAES Graduate School at the NIH. He is a member of the Board of Directors for the Antibody Society and the Chair of the Scientific Advisory Board for the Chinese Antibody Society, and the Editor-in-Chief of Antibody Therapeutics (Oxford University Press). Dr. Ho studies the biology of cancer driven by cell surface proteins, such as mesothelin and glypicans (e.g. GPC3, GPC2), in broad scientific fields of molecular biology with focus on ligand/receptor interactions, antibody/nanobody engineering, and cancer immunotherapy. He has received many honors including the APAO Scientific Achievement Award, NIH DDIR Innovation Award, and NCI Director's Innovation Award.

DR. ANANT JANI

Dr. Jani is an Oxford Martin Fellow at the Oxford Martin School at the University of Oxford as well as an Advisory Board member for Value Based Managed Care GmbH, a subsidiary of the Gothaer Group and IC2PerMed (Integrating China in the International Consortium for Personalized Medicine - https://www.ic2permed.eu/). Anant currently works on understanding how to utilize digital health, big data and analytics to address social determinants and making healthcare systems more sustainable. Prior to this, he served as the Executive Director of Better Value Healthcare, a boutique advisory firm supporting national, regional and local healthcare systems in England, Scotland, Wales, Germany, Italy, Spain, Netherlands, Saudi Arabia, Qatar, Singapore, Canada and the US. He received his PhD from Yale University and undergraduate degrees from Brandeis University.

# SPEAKERS BIOGRAPHY IN ALPHABETICAL ORDER

## DR. YANG LIU, PH.D.

Dr. Liu is a Professor and the Director at Division of Immunotherapy, Institute of Human Virology, University of Maryland Baltimore. He also serves as Chairman of OncoImmune, Inc. Dr. Liu's laboratory established Sialoside-based pattern recognition as a mechanism of self-nonself discrimination in innate immunity. Dr. Liu co-founded and led OncoImmune, Inc that obtained clinical proof-of-concept data in a multi-center, randomized double blind clinical phase II trial showing that our first-in-class new drug significant increase overall survival of leukemia patients receiving hematopoietic stem cell transplantation. The Company will soon finish a double-blinded randomized Phase III clinical trial testing the significance of this pathway in treating severe and critical COVID-19 patients. Dr. Liu is a recipient of many awards and honors, including Irvington Fellowship, Markey Scholar Award, Searle Scholar Award, AAAS Fellow, League of Research Excellence, University of Michigan, and Snyder Award for outstanding cancer research, George Washington University.

## FELICIA PULLAM

Felicia is Regional Manager for East Asia, Maryland Department of Commerce. She assists Chinese companies that want to establish operations in Maryland. She coordinates Maryland's strategy to promote foreign direct investment (FDI) from around the world. She also helps Maryland companies expand to China, Japan, Korea, and Southeast Asia.

Before joining the Maryland team, Felicia was the Deputy Assistant Secretary for Textiles, Consumer Goods, and Materials at the U.S. Department of Commerce where she oversaw trade policy implementation for a large swath of the U.S. economy. She also served as the Director of Outreach and Communications for SelectUSA, the federal program to promote FDI into the United States.

Prior to her federal service, Felicia helped lead trade and FDI for the State of Delaware, after spending nearly a decade in China managing APCO Worldwide's China and Asia-wide Corporate Responsibility and Sustainability practices. She got her start in international affairs in 2000 through the Princeton in Asia program in Guangzhou, followed by a yearlong adventure as tutor and translator for Chinese actress Zhang Ziyi.

## DR. DONG SHEN, PH.D., M.D.

Dr. Dong Shen is founder and CEO of RNAimmune, Inc. Dr. Shen graduated with PhD degree from Johns Hopkins University School of Medicine with Dr. Bert Vogelstein and MD degree from Shanghai Jiao Tong University School of Medicine. Dr. Shen led numerous TCGA projects, breast cancer project with Dr. Elaine Mardis from WashU genome institute, AML project with Dr. Tim Lay and Dr. Matt Walter from WashU school of medicine, and MDS project with Dr. Tim Graubert from Harvard school of medicine. Dr. Shen has extensive drug development experience in AstraZeneca and Johnson and Johnson, having led projects across multiple therapeutic areas with high unmet medical need. Dr. Shen was the recipient of Johnson & Johnson leadership award in 2018 and innovation award in 2017. All his manuscripts have been published at the most influential journals, such as Science, Nature, Cell, JAMA, New England Journal of Medicine, and etc. The total number of publications citations is over 17,700. Currently, Dr. Shen and his team are developing mRNA vaccine and antibodies fighting against novel coronavirus outbreak.

## DR. JOAN (HUAQIONG) SHEN, PH.D.

Dr. Shen obtained her PhD in life science and is a licensed physician with board certification in US. She had postdoctoral trainings in endocrinology, psychopharmacology and clinical pharmacology. Being responsible for global clinical development programs cross phase 1-4, she worked in Eli Lilly & Co, Wyeth and Pfizer in US, and gained extensive experiences of working with FDA, EMEA, CFDA, PMDA, KFDA and etc.

Joan was sent by Pfizer in 2011 as the China Clinical Head. She later joined Hengrui Pharmaceutical as the CMO. In Hengrui, she built the largest clinical team among China domestic pharmas and led the successful conduction of clinical trials in China, USA and Australia. Joan joined Janssen Pharmaceutical Companies of Johnson & Johnson as the Development Head of China in 2015, where she led multiple successful NDA approvals in China. During this time, she is elected as the co-chair of RDPAC R&D core team and played very important role in authoring "Fostering a Sustainable Ecosystem for Drug Innovation in China". Joan joined I-Mab Biopharma as the Head of R&D in 2017 and was promoted to CEO in October 2019.

Joan is elected as the executive committee member of China New Drug Research Evaluation Committee. She holds academic positions as the guest professor of Beijing University Clinical Research Institute and was the adjunctive professor of Indiana University School of Medicine.

# SPEAKERS BIOGRAPHY IN ALPHABETICAL ORDER

DR. GEORGE SIBER, M.D.

Dr. Siber is an infectious disease trained physician with more than 40 years of experience in developing vaccines and antibody products. From 1996 to 2007, Dr. Siber served as Executive Vice President and Chief Scientific Officer of Wyeth Vaccines (now Pfizer). While at Wyeth, Dr. Siber led the development and approval of multiple innovative childhood vaccines, including Prevenar7 and Prevenar13, the first pneumococcal conjugate vaccines which have had a significant impact on mortality globally and which have achieved multibillion dollar revenues; Rotashield, the first rotavirus diarrhea vaccine, Meningitec, the first meningococcal meningitis conjugate vaccine and FluMist, the first nasal influenza vaccine. Prior to Wyeth, Dr. Siber was Director of the Massachusetts Public Health Biologic Laboratories and a Harvard Medical School Associate Professor of Medicine at Dana Farber Cancer Institute. During this time, Dr. Siber led the research and manufacturing of multiple vaccines and immune globulins including Respigam, a human immune globulin against respiratory syncytial virus. Dr. Siber currently is a Co-founder and Board Member of Affinivax and serves on the BOD of Genocea. Dr. Siber is a member of the SAB of CureVac, Valneva, Vaxess, AdVaccine and ILiAD and serves as a consultant to the Gates Foundation, PATH and the Wellcome Trust. Dr Siber has received multiple awards including the 2016 Albert Sabin Gold Medal in vaccinology. Dr. Siber holds an MD degree from McGill University in Canada, received post doctoral training in Internal Medicine at Rush Presbyterian Hospital in Chicago and Beth Israel Hospital in Boston and training in Infectious Diseases and Vaccinology at Children's Hospital and Beth Israel Hospital, Harvard Medical School, Boston.

DR. PETER STEIN, M.D.

Dr. Stein is the Director of CDER's Office of New Drugs (OND). OND is responsible for the regulatory oversight of investigational studies during drug development and decisions regarding marketing approval for new (innovator or non-generic) drugs, including decisions related to changes to already marketed products. OND provides guidance to regulated industry on a wide variety of clinical, scientific, and regulatory matters. A nationally-recognized leader in pharmaceutical research and development, Dr. Stein joined CDER in 2016 as the OND Deputy Director. Before coming to FDA, he served as Vice President for late stage development, diabetes, and endocrinology at Merck Research Laboratories. He also served as Vice President, head of metabolism development at Janssen. He has more than 30 years of academic, clinical, and industry experience. Dr. Stein holds a bachelor's degree in history from the University of Rochester in New York and a medical degree from University of Pennsylvania. He trained at Yale University and Yale-New Haven Hospital in internal medicine and in endocrinology and metabolism.

JOHN C. WOBENSMITH

John C. Wobensmith was appointed as the Secretary of State by Maryland Governor Larry Hogan in January 2015 and confirmed by the Maryland State Senate in February 2015.

The Secretary of State is responsible for handling certain executive functions including Executive Orders, extraditions and requisitions, pardons and commutations, public disclosures with persons doing business with the State, certifying candidates for nomination by a principal political party on the presidential primary ballot. The Secretary of State chairs the Governor's Subcabinet on International Affairs, which is responsible for evaluating the State's international activity, devising a coordinated strategy that enhances Maryland's competitiveness in world markets, and overseeing protocol functions. The Maryland Sister States Program is also conducted under the auspices of the Office of Secretary of State.

Secretary Wobensmith has over 45 years of experience in the national security field. He began his career at the National Security Agency from 1967 to 1993 with various critical assignments and served three different tours at the White House. From 1993 to 1997, he was the senior U.S. Department of Defense representative in Turkey. Secretary Wobensmith has also served as a Senior Advisor and Vice President for Development of the American Foreign Policy Council (2005-08), Vice President for External Affairs and Lecturer in Intelligence for the Institute of World Politics (1999-05), and Vice President for International Marketing for Sensys Technologies, Inc. (1997-98).

Secretary Wobensmith received a Bachelor of Arts in English from the University of Pennsylvania, served in the U.S Navy, and is a graduate of the National War College. He is a recipient of the National Intelligence Distinguished Service Medal, the Secretary of Defense Meritorious Civilian Service Award, and the National Security Agency Meritorious Civilian Service Award. In 2016, he was awarded the prestigious Ellis Island Medal of Honor by the National Ethnic Coalition of Organizations (NECO). The Secretary resides in Annapolis and has been married to his wife, Judi, for 50 years. He has two children and four grandchildren.

# SPEAKERS BIOGRAPHY IN ALPHABETICAL ORDER

DR. JINGHUA YAN, PH.D.

Dr. Jinghua YAN, a professor and Principle Investigator in Institute of Microbiology, Chinese Academy of Sciences, China.

She obtained Ph.D from Institute of Bioengineering, Academy of Military Medical Sciences, and joined in Institute of Microbiology in 2004. She became a Principle Investigator in 2014. She mainly focuses on the development of vaccines and therapeutic antibodies. Dr. Yan's Group developed subunit vaccine for H5/H7 Avian influenza and dimer subunit vaccine for MERS and SARS-CoV-2. She has developed the humanized antibodies against MERS coronavirus, and screened out the human neutralizing antibodies of Zika virus, RVFV, and SARS-CoV-2.

She has published more than 90 papers (Including papers in Nature, Science, Cell, Sci Transl Med, Cell Res, etc.), and holds more than 20 patents. She has obtained one Second Class Prizes of The State Scientific and Technological Progress Award in 2014, one First Class Prizes of Science and Technology Award form Chinese Preventive Medicine Association in 2017 and the Outstanding Scientific Research Team Award of Qiu Shi in 2019.

DR. DAJUN YANG, PH.D.

Dr. Dajun Yang is the Chairman and CEO of Ascentage Pharma. Dr. Yang has dedicated his career to the research on apoptosis and innovative drug R&D for nearly 30 years. In 2009, he co-founded Ascentage Pharma and made major breakthroughs in the research of development of precision drugs targeting apoptosis and autophagy dual-channel regulation. Ascentage Pharma is the only company in the world that researches and develops innovative drugs targeting all of these pathways. Ascentage Pharma currently has eight potential "First-in-class" or "Best-in-class" innovative drug candidates in Phase I/II clinical developments in China, the United States and Australia. Dr. Yang has undertaken nearly ten National Science and Technology Major Projects such as the National High-tech R&D Program (the "863 Program") and the Major Innovative Drug Developments program. The team led by Dr. Yang has won multiple awards such as the Major Innovation Team of Suzhou and Jiangsu, the First Jiangsu Innovation Competition Team Award, and the R&D Achievement of the Year 2017 from the BayHelix Group. Dr. Yang is the recipient of the 2018 "Dushu Lake Prize" for the Most Influential Leader in Drug R&D an award widely recognized in the field drug R&D. Dr. Yang was the president of Chinese Biopharmaceutical Association-USA from 2005 to 2006 and has concurrently served as professor and Ph.D. supervisor at Sun Yat-sen University Cancer Center, vice director of the Drug R&D Specialty Committee of China Pharmaceutical Innovation and Research Development Association, and part-time researcher in Pharmaceutical Innovations at Shanghai Institute of Materia Medica, Chinese Academy of Sciences.

DR. YIHONG YAO, PH.D.

Dr. Yihong Yao is the chief scientific officer of Cellular Biomedicine Group, Inc (CBMG). He is responsible for development of cell therapy clinical pipeline, implementation of translational medicine strategies, and plays a key role in all phases of clinical development at CBMG.

Previously Dr. Yao was director and head of Pharmacogenomics and Bioinformatics at MedImmune/Astrazeneca. He served on the executive team for immune-oncology pipeline development at MedImmune/Astrazeneca. He also worked at Abbott Bioresearch Center focusing on development of biomarker for preclinical and clinical development.

Dr. Yao has authored over 60 peer-reviewed publications, edited two books and has over issued 20 patents.

# SPEAKERS BIOGRAPHY IN ALPHABETICAL ORDER

## DR. WENHONG ZHANG, M.D.

Dr. Zhang Wen-Hong (张文宏) is Professor and Head of the Center for Infectious Disease, Huashan Hospital of Fudan University in Shanghai. As the Chief of the Department of Internal Medicine of Fudan University in Shanghai, Dr. Zhang is the leader of Shanghai's Anti-COVID-19 clinical expert team. He has extensive experience with the diagnosis and treatment of various emerging infectious diseases. Dr. Zhang is a graduate of Shanghai Medical University and has held visiting scholar and postdoctoral fellow positions at the Department of Microbiology at the University of Hong Kong, Harvard Medical School and Illinois State University at Chicago.

## DR. TONGQING ZHOU, PH.D.

Dr. Tongqing Zhou is Chief of the Structural Bioinformatics Section, Vaccine Research Center, NIAID, NIH. His research mainly focuses on structural basis of broadly neutralizing HIV-1 antibodies and structure-based design and testing of novel vaccines for HIV. Recently, Dr. Zhou also expanded his research into other infectious diseases, such as SARS-CoV-2, RSV, Influenza, hPIV, Zika, MERS and HCMV. Dr. Zhou has published more than 80 peer-reviewed research papers in profession journals, including Nature, Science and Cell. He is a Clarivate Analytics (Thompson Reuters) Highly Cited Researcher in Microbiology in 2014, 2015, 2017, 2018 and 2019, and recipient of NIAID Merit Awards. Dr. Zhou is co-inventor of several patents on potential HIV, RSV and HPIV vaccines and therapeutic antibodies, of which broadly neutralizing antibody VRC01 is in advanced clinical trial.

Dr. Zhou received B.S. in Biochemistry from Wuhan University, China, in 1989 and Ph.D. in Cell Biology from the Chinese Academy of Sciences in 1994. Before joining the VRC in September 2001, Dr. Zhou was a postdoctoral research associate at Wayne State University School of Medicine, where he obtained his x-ray crystallography training and M. Sc. in Electrical and Computer Controlled Systems. For more information, please visit: https://www.niaid.nih.gov/research/tongqing-zhou-phd.

# CBA PAST 10-YEAR AWARD RECIPIENTS

## CBA Brilliant Achievement Award Recipients

The CBA Brilliant Achievement Award was established in 2003 to honor outstanding individuals who have made seminal contributions to science, technology, or business development in the biopharmaceutical fields; whose vision has moved medicine in new directions; and who has been actively involved in building collaborative efforts internationally to advance medical fields. The Award also aims to promote public awareness of the importance of collaborations between basic and applied researchers, between academia and industry, and between researchers and entrepreneurs.

**2019** AARON CIECHANOVER, M.D., Ph.D., Distinguished University Professor, Faculty of Medicine, Technion-Israel Institute of Technology; 2004 Nobel Prize Laureate in Chemistry

**2018** LIEPING CHEN, M.D., Ph.D., Professor, Yale University

YONG-JUN LIU, M.D., Ph.D., Head of Research, Global R&D Sanofi

RICHARD PAZDUR, M.D., Director, Oncology Center of Excellence, US FDA

LAURENCE J.N. COOPER, M.D., Ph.D., CEO, Ziopharm Oncology

**2017** J. CRAIG VENTER, Ph.D., Executive Chairman, Human Longevity Inc.; Founder, Chairman and CEO of the J. Craig Venter Institute; Co-Founder, Executive Chairman and Co-Chief Scientist, Synthetic Genomics Inc.

ROBERT TEMPLE, M.D., Deputy Director of Clinical Science, FDA CDER

**2016** BAHIJA JALLAL, Ph.D., Executive VP of AstraZeneca

GE LI, Ph.D., CEO and Chairman of Board of Directors, WuXi AppTec

**2015** ZHU CHEN, Ph.D. Professor, Shanghai Jiao Tong University; President, the Red Cross Society of China; Former Minister of Health, China

BARRY K. SHARPLESS, Ph.D., W.M. Keck Professor of Chemistry, Scripps Institute; 2001 Nobel Laureate in Chemistry

**2014** JAMES F. YOUNG, Ph.D. Chairman of Board of Directors, NovaVax, Inc.

**2013** JAMES L. HUGHES, MBA, President, UM Health Sciences Research Park Corporation, University of Maryland Baltimore

**2012** BERNARD ROIZMAN, Sc.D., Joseph Regenstein Distinguished Service Professor of Virology, University of Chicago

JINGSHENG REN, Founder, Chairman and CEO, Simcere Pharmaceutical Group

**2011** JONATHAN M. ROTHBERG, Ph.D., Founder and CEO, Ion Torrent Corporation

THOMAS WATKINS President and CEO, Human Genome Sciences Inc (now part of GSK)

**2010** ERIC GREEN, M.D., Ph.D., Director, National Human Genome Research Institute, NIH

KINYIP GABRIEL LEUNG,, M.S., Executive Vice President, OSI Pharmaceuticals, Inc.

**2009** LUC MONTAGNIER, M.D., Emeritus Professor, C.N.R.S. of France; 2008 Nobel Laureate of Physiology and Medicine

ROBERT C. GALLO, M.D., Professor, University of Maryland

## CBA Outstanding Service Award Recipients

The CBA Outstanding Service Award was established in 2003 to honor individuals who have made significant contributions to CBA.

**2019** SHAO-BAI CHAO, PH.D., COO of CanSino Biologics Inc.

**2018** ZIPING WEI, PH.D., Co-Founder and CEO of BlissBio

**2017** PING CHEN, Ph.D., Founder and CEO of Anyu Biomed Inc.

**2016** RICHARD ZHAO, Ph.D., Professor, University of Maryland School of Medicine

**2015** ZHIFENG LONG, Ph.D., President, Peronsal Diagnostix

**2014** SUJUAN BA, Ph.D., Chief Operating Officer, National Foundation for Cancer Research

**2013** YIFAN ZHAI, M.D., Ph.D., CEO & President, Healthquest Pharma

**2012** LIN SUN-HOFFMAN, J.D., Ph.D., President, Sun-Hoffman Consulting

**2011** YULING LI, Ph.D., Fellow, Process Biochemistry, MedImmune

**2010** DAJUN YANG, M.D., Ph.D., Co-Founder, Chairman & CEO, Ascentage Pharma Group Corp.

**2008** YINGXIAN XIAO, Ph.D., Associate professor, Georgetown University School of Medicine

# CBA PAST PRESIDENTS AND CONFERENCES

| Year | Annual Conferences | President | Theme | Place |
|---|---|---|---|---|
| 1996 | 1st | Guoliang Yu | Biotechnology: Today and Tomorrow | Washington, USA |
| 1997 | 2nd | Patrick Lu | Biotechnology: From Bench to Market Place | Washington, USA |
| 1998 | 3rd | Patrick Lu | Biotechnology: From USA to China | Washington, USA |
| 1999 | 4th | Sun Lu | Biotechnology: Genomics and Beyond | Washington, USA |
| 2000 | 5th | Wei-wu He | Biotechnology: Genomics in the Information Age | Washington, USA |
| 2001 | 6th | Jian Ni | Biotechnology: From Research to Commercialization in Life Science Industry | Washington, USA |
| 2002 | 7th | Jian Ni | Drug Development in USA and China: Impact of Human Genome Project and World Trade Organization | Washington, USA |
| 2003 | 8th | Yingxian Xiao | Biotechnology & Pharmaceutical Industry: Technology Platforms and Business Models | Washington, USA |
| 2004 | 9th | Roxanne Duan | Trends in Biotechnology: New Strategies and Perspectives | Washington, USA |
| 2005 | 10th | Dajun Yang | Biopharmaceutical Globalization: Strategies and Perspectives | Washington, USA |
| 2006 | 11th | Dan Zhang | Dynamic Changes in the Biopharmaceutical Industry: Challenges and Opportunities | Washington, USA |
| 2007 | 12th | Yuling Li | Dynamic Biopharmaceutical Development: from Discovery to Commercialization | Washington, USA |
| 2008 | 13th | Lin Sun-Hoffman | Biotechnology Innovation and Sustainable Development | Washington, USA |
| 2009 | 14th | Yifan Zhai | Biopharmaceutical Innovation and Commercialization | Guangzhou, China |
| 2010 | 15th | Sujuan Ba | Biopharmaceutical Medicines: Development and Commercialization without Boarders | Washington, USA |
| 2011 | 16th | Zhifeng Long | From Personal Genomes to Translational Medicine | Washington, USA |
| 2012 | 17th | Richard Zhao | Emerging Market for Biopharmaceutics in Asia: Opportunities and Challenges | Qingdao, China |
| 2013 | 18th | Ping Chen | Global Partnership in Biopharmaceutics and Translational Medicine | Washington, USA |
| 2014 | 19th | Ziping Wei | Advancement and Global Opportunities in Innovative Biopharmaceutical Development | Washington, USA |
| 2015 | 20th | Shao-Bai Chao | Globalization of Biopharmaceutical Development and Commercialization - Emerging Market Opportunities | Lianyungang, China |
| 2016 | 21st | Xu-Rong Jiang | Biopharm US-China: Accelerating Global Development and Commercialization through Partnership | Washington, USA |
| 2017 | 22nd | Dong Shen | Delivering Lifesaving Medicines to Patients through Innovation, Regulatory Reform and Global Partnership | Washington, USA |
| 2018 | 23rd | Frank Li | Bridging Innovations, Entrepreneurs & Opportunities to Advance Global Biopharmaceuticals Development | Washington, USA |
| 2019 | 24th | Julia Chuanhua Xing | Transforming Biopharmaceutical and Healthcare Industry through Cutting Edge Technologies and Global Partnership | Guangzhou, China |

## The Organizing Committee of CBA 25th Annual Conference

CHAIRMAN: DR. DAZHI (ALEX) LAI

DR. XURONG JIANG

DR. FRANK LI

DR. HAO LI

DR. HANG LU

DR. JULIA LUAN

DR. HELEN MAO

MS. APRIL HUANG

DR. DONG SHEN

DR. SONG WU

DR. YULING WU

DR. ZHIQIANG WANG

DR. JULIA XING

DR. HARRY YANG

DR. JUDY YU

Leads Biolabs

关爱生命 专注创新 合作共赢

Care for life, focus on innovation and win-win collaboration

# 南京维立志博生物科技有限公司
NANJING LEADS BIOLABS Co.,Ltd

## About us

南京维立志博生物科技有限公司是一家创新驱动的临床阶段生物制药公司致力于具有自主知识产权的治疗肿瘤和其他重大疾病的抗体新药研发，拥有多个单克隆和双特异性抗体项目组成的研发管线，特别聚焦新型的肿瘤免疫治疗抗体。公司将不断开拓创新，为广大患者提供安全、有效、可及、可负担的抗体新药，满足尚未满足的医药需求。

Nanjing Leads Biolabs Co., Ltd. is an innovation-drivenclinical-stage biopharmaceutical company, committed to the R&D of therapeutic antibody drugs for cancer and other major diseases with multiple novel monoclonal and bispecific antibodies in its rich pipeline, especially focusing on the immune-oncology antibody drugs. The company will strive for innovation providing safe,effective, accessible and affordable new drugs for patients to meet unmet medical needs.

## R&D pipeline

| Project* (Indication) | Lead | Candidate | Cell line | Pre-clinical | IND | Ph-I |
|---|---|---|---|---|---|---|
| mAb: LBL-007（solid tumor） | Synergistic to αPD-1 | | | IND Aug 2019 in China Feb 2020 in U.S.A. | | China 2020 |
| mAb: LBL-003（solid tumor/hematology malignancies） | Synergistic to αPD-1 | | | | Target IND: Q3 2020 | |
| Bispecific antibody-fusion protein: LBL-015（solid tumor） | PD-1 2.0 PD-1 blockade & change TME | | | | Target IND: Q4 2020 | |
| Bispecific antibody: LBL-024（solid tumor） | T cell-tumor engaging for cold tumors | | | | Target IND: Q2 2021 | |
| mAb: LBL-019（solid tumor） | Change TME | | | | Target IND: Q4 2021 | |

**Contact us**
Tel：025-83378099
E-mail： wlzb@leadsbiolabs.com
Website：www.leadsbiolabs.com

# SPONSOR HIGHLIGHTS

## COSPONSOR

Maryland
OPEN FOR BUSINESS

We welcome you to Maryland! Our state is in the prime commercial corridor between New York and Washington, D.C. We offer you world-class transportation infrastructure, 350 research centers, and a diverse, highly skilled workforce. Maryland is home to the National Institutes of Health, the Food and Drug Administration, the headquarters of the Chinese Biopharmaceutical Association, Johns Hopkins University, the University of Maryland, and many others. We have the highest concentration of Ph.D. scientists and engineers and more federal research and development investment than any other state. A leader in vaccine development and adult stem cell production, the state's rapidly growing ecosystem also includes biotech, pharmaceuticals, genomics, medical devices, Traditional Chinese Medicine, personalized and regenerative medicine, and more. The Maryland Department of Commerce can help you establish your business and find success in the United States. Please contact our office in China: Ning Shao, ningshao@mccusa.org / or our office in Baltimore: Felicia Pullam, felicia.pullam@maryland.gov.

## DIAMOND

Leads Biolabs 维立志博

Nanjing Leads Biolabs Co., Ltd. is an innovation-driven clinical-stage biopharmaceutical company, committed to the R&D of therapeutic antibody drugs for cancer and other major diseases with multiple novel monoclonal and bispecific antibodies in its rich pipeline, especially focusing on the immune-oncology antibody drugs. The company will strive for innovation providing safe, effective, accessible and affordable new drugs for patients to meet unmet medical needs.

## GOLD

sirnaomics
Advancing RNAi Therapeutics

Sirnaomics, Inc. is the only company having Innovative Platform for Novel siRNA Therapeutic Clinical Studies focus on the unmet needs including Fibrosis, Cancer & Viral Infection in both USA and China. Patrick Lu, serves as a "1000 Talents" expert and the PI of "12-5" Key Programs for innovative pharmaceuticals in China founded this company with his experienced team. Sirnaomics STP705 is entering clinical Phase IIa in USA and approved for clinical study as the 1st ever ONT drug in China.

DORSEY™
DORSEY & WHITNEY LLP

Dorsey & Whitney LLP is a U.S. law firm with over 107 years of history and 19 offices around the world, including in the U.S., China (Beijing, Shanghai and Hong Kong), Canada and the U.K. Dorsey is consistently ranked as a top law firm by *The American Lawyer and Chambers & Partners*. Dorsey is also recognized as a "BTI Client Service A-Team".

Dorsey has served clients in the healthcare industry since the 1940s. The firm's Life Science and Healthcare Industry Group consists of about 120 specialized attorneys serving more than 500 clients. We serve clients ranging from companies at the forefront of medical innovation to the largest health care payer in the United States (United Healthcare Group) to one of the world's most recognizable medical practices (Mayo Clinic). Life sciences and healthcare companies rely on Dorsey because our attorneys understand the legal and technical issues crucial to success in this rapidly changing industry. Our wide range of expertise and experience, which includes attorneys with scientific degrees and industry backgrounds, provides a framework for our clients' success – from patent applications, regulatory compliance and licensing agreements to mergers and acquisitions, national security analysis (CFIUS and export control), litigation, private equity and venture capital financings and IPOs.

Dorsey has a dedicated team of Chinese-English bilingual attorneys within its U.S.-China Practice Group assisting Chinese clients, led by prominent international lawyer Catherine Pan-Giordano, a partner based in our New York office. Given their language and culture background, attorneys in our U.S.-China Practice Group can fully understand the needs of Chinese clients and clearly explain U.S. legal matters to these clients.

For more information about Dorsey, please visit: www.dorsey.com.

## SPONSOR HIGHLIGHTS

SILVER

CanSinoBIO

CanSino Biologics Inc. (CanSinoBIO, SHSE: 688185, HKEX:06185) is an innovative biopharmaceutical company dedicated to exploring best solutions to the prevention of diseases through cutting edge research & development, advanced manufacturing and commercialization of innovative vaccine products for human use worldwide.

Since its establishment in Tianjin, China in 2009, CanSinoBIO has experienced tremendous growth with now more than 600 employees, one approved vaccine for Ebola virus disease (Ad5-EBOV) and 16 vaccine candidates in the product pipeline. CanSinoBIO has been listed on the Main Board of Hong Kong Exchange and Clearing Limited (HKEx) in March 2019. A year later, CanSinoBIO has successfully listed on the Sci-Tech Innovation Board (STAR Market) of the Shanghai Stock Exchange, making it the first "A+H" dual listing vaccine company. CanSinoBIO is focusing on continually expanding manufacturing capacity for its current vaccine candidates and further enhancing the competitiveness and the scope of its portfolio by promoting the R&D of new vaccine candidates.

Leveraging broad experiences of our accomplished team of scientists and business leaders who had previously held technical and senior management positions at many of the leading pharmaceutical companies in the world, including Sanofi Pasteur, Astra Zeneca, Wyeth (now Pfizer) and CNBG (China), CanSinoBIO has developed four key platform technologies, including adenovirus-based viral vector vaccine, conjugation, protein structure design and recombination as well as vaccine formulation technologies.

In addition, the company has in-licensed a number of new technologies and intellectual properties through collaborations with international research organizations and biotechnology companies. CanSinoBIO collaborates through partnerships with world-class academic centers or start-up companies that develop innovative technologies, to prepare the portfolio of the next decades and ensure sustainable growth of the company.

CanSinoBIO is currently developing 16 vaccine candidates for 13 infectious disease areas, preventing meningitis, pneumonia, tuberculosis, COVID-19, Ebola virus disease, pertussis, diphtheria, tetanus, shingles etc. Among these, Ad5-EBOV, the globally innovative Ebola virus disease vaccine, has received NDA (New Drug Application) approval in China in October 2017. The NDA applications of two meningococcal conjugate vaccines are under NMPA review. Moreover, Ad5-nCoV, the investigational vaccine against COVID-19 has been approved to enter into phase I clinical trial. At present, CanSinoBIO has seven vaccine candidates in the clinical trial stage or clinical trial application stage. There are also six pre-clinical vaccine candidates under development, including one combination vaccine candidate.

CanSinoBIO currently has a Research and Development Center with a floor space of approximately 120,000 square-feet as well as a 380,000 square-feet commercial manufacturing campus, which is designed, qualified and operated according to international cGMP standards (FDA, EU, WHO and China). The GMP pilot plants located in the R&D center have passed EU QPs' audits. The annual bulk production capacity of the current facilities can reach approximately 70 million to 80 million doses, which will be capable of supporting our commercialization plans for our near-commercial vaccine candidates.

Vaccination is an essential part of effective disease control and prevention. CanSinoBIO is committed to make innovative and high quality vaccines accessible to people all over the world thus empower people to pursue healthy and better life.

## SPONSOR HIGHLIGHTS

## SPONSOR HIGHLIGHTS

BRONZE

君实生物 TopAlliance

Established in 2012, Junshi Biosciences is committed to developing first-in-class and best-in-class drugs through original innovation and becoming a pioneer in the area of translational medicine to provide patients with effective and affordable treatment options. Junshi Biosciences was dual listed on the Main Board of the Stock Exchange of Hong Kong (stock code: 1877.HK) and Shanghai STAR Board (Stock code: 688180.SS). The Company has established a diversified R&D pipeline comprising 21 drug candidates with therapeutic areas covering cancer, metabolic diseases, autoimmune diseases, neurologic diseases, and Infectious disease. Product types include monoclonal antibodies, fusion proteins, antibody-drug conjugates, and small molecule drugs. With a combined 33,000L fermentation capacity in two GMP-facilities at Shanghai and Suzhou, Junshi has established the manufacturing infrastructure to support commercialization and provide our partners and patients with high-quality products through a global supply chain network. For more information, please visit: http://junshipharma.com.

RJBIO

RJ Bio Process (Suzhou) Co., Ltd. is founded by Mr. Frank GJ Ding in Dec. 2011, who is expert at the marketing and sales in the field of pharm and bio pharm for more than 20 years. RJ Bio supplies both the high quality products developed by the experienced engineers from RJ and those with the innovative technologies from US and European partners.

RJ Bio developed the down steam products line like " Smart diaphragm pump " and " in-line dilution chromatograph skids " which combine the intelligence automation with the PAT technology for the GMP / c-GMP production of large molecule protein. RJ has near 60 staff at Suzhou covering R&D, production, quality and administration. With the improvement of the existing iCE instrument technology, RJ Bio develops the product line of formulation analytics. We represent the instruments with the last technology for the protein formulation development, like the FlowCam for sub visible particle testing and the Argen for protein aggregation rate testing. We are looking for more new products designed for this application.

I-MAB BIOPHARMA

I-Mab (Nasdaq: IMAB) is a dynamic, global biotech company exclusively focused on discovery, development and soon commercialization of novel or highly differentiated biologics in the therapeutic areas of immuno-oncology and autoimmune diseases. The Company's mission is to bring transformational medicines to patients around the world through innovation. I-Mab's innovative pipeline of more than 10 clinical and pre-clinical stage drug candidates is driven by the Company's Fast-to-PoC (Proof-of-Concept) and Fast-to-Market development strategies through internal R&D and global partnerships. The Company is on track to transitioning from a clinical stage biotech company toward a fully integrated global biopharmaceutical company with cutting-edge R&D capabilities, world-class GMP manufacturing facility and commercial capability. I-Mab has offices in Beijing, Shanghai, Hong Kong and Maryland, United States. For more information, please visit http://www.i-mabbiopharma.com

# SPONSOR HIGHLIGHTS

HOPSTEM BIOTECHNOLOGY

Hopstem, an innovative biomedical company focusing on development of CNS cell replacement therapy and iPSC disease models.

Hopstem Bioengineering Ltd. Co was established in Hangzhou, 2017, by neuroscience and stem cell scientists from Johns Hopkins University. Hopstem has established a world-leading platform of differentiating human embryonic stem cells (ESC) or induced pluripotent stem cells (iPSC) into high quality neural progenitor cells and functional subtypes of neural cells. Hopstem devoted to developing cell replacement therapies with GMP-grade neural cells for those who suffer from neurological disorders, including stroke, traumatic brain injury, AD, PD and ALS, etc. On the other hand, Hopstem also provides physiological relevant human neural cells, brain organoids and services to promote in vitro disease modeling for drug discovery, high throughput drug screening, and toxicology studies for CNS disorders. With developed patents in iPSC reprogramming, neural differentiation and 3D brain organoids technology innovation, Hopstem was voted among "Top 50 Most Innovative Chinese Biomedical Companies in 2019". Hopstem has a strong team with MDs/Ph.Ds and top scientist/industrial advisors in the field. The company has finished two rounds of fund raising and is conducting pre-IND study of the first pipeline – neural progenitor cell replacement therapy for chronic stroke.

AMADOR BIOSCIENCE 安渡生物

Amador Bioscience is a global translational and clinical CRO, providing global-standard (GLP/GCP) laboratory, clinical research, clinical pharmacology, and regulatory filing services to leading pharmaceutical companies in both China and the U.S. The laboratory services focus on bioanalysis, biomarkers and immunogenicity assessment. The clinical research unit specializes in innovative clinical development strategy, protocol design, study initiation and monitoring of clinical studies in China and the U.S. In addition to the R&D strategy and regulatory pathway, the clinical pharmacology services perform global-standard data analysis and generate submission-ready study reports.

Amador team, 25% with doctoral degree (PhD, MD, PharmD) and 40% with master degree, have extensive experience and in-depth expertise in clinical pharmacology, biostatistics, programing, bioanalysis, biomarkers, clinical medicine, clinical trial management, data management, project management, quality assurance, and regulatory submission.

Amador is committed to supporting innovative drug development from early drug discovery to clinical development and regulatory filling. We are providing global-standard, integrated services for dozens of companies in China & U.S. (more than 50% from U.S.), including a number of successful IND/BLA filings in both China and U.S. Amador Bioscience operates in the U.S. (San Francisco Bay Area, Virginia, etc.) and China (Hangzhou and Beijing).